Regeneron Pharmaceuticals, Inc. (REGN)

Basic

  • Market Cap

    $89.35B

  • EV

    $76.36B

  • Shares Out

    106.35M

  • Revenue

    $13.1B

  • Employees

    12,463

Margins

  • Gross

    53.09%

  • EBITDA

    36.76%

  • Operating

    33.65%

  • Pre-Tax

    33.41%

  • Net

    30.47%

  • FCF

    35.16%

Returns (5Yr Avg)

  • ROA

    15.6%

  • ROE

    32.21%

  • ROCE

    29.1%

  • ROIC

    32.88%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $912.57

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $122.63

  • Earnings (Dil)

    $35.06

  • FCF

    $40.46

  • Book Value

    $234.46

Growth (CAGR)

  • Rev 3Yr

    18.17%

  • Rev 5Yr

    15.52%

  • Rev 10Yr

    21.24%

  • Dil EPS 3Yr

    8.71%

  • Dil EPS 5Yr

    17.55%

  • Dil EPS 10Yr

    17.44%

  • Rev Fwd 2Yr

    5.29%

  • EBITDA Fwd 2Yr

    -4.86%

  • EPS Fwd 2Yr

    -1.8%

  • EPS LT Growth Est

    4.08%

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM
Metric
Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
LTM

Revenues

5,016.6

6,383.6

7,940.1

15,790.5

11,807.8

12,646.0

Other Revenues, Total

129.0

174.0

557.0

281.2

365.1

451.3

Total Revenues

5,145.6

6,557.6

8,497.1

16,071.7

12,172.9

13,097.3

Total Revenues % Chg.

-12.4%

27.4%

29.6%

89.1%

-24.3%

-4.5%

Cost of Goods Sold, Total

1,886.3

3,215.1

3,766.9

5,297.6

5,152.9

6,144.3

Gross Profit

3,259.3

3,342.5

4,730.2

10,774.1

7,020.0

6,953.0

Selling General & Admin Expenses, Total

1,127.2

1,341.9

1,346.0

1,824.9

2,115.9

2,554.1

Other Operating Expenses

-402.3

-209.2

-280.4

-45.6

-89.9

-8.2

Other Operating Expenses, Total

724.9

1,132.7

1,065.6

1,779.3

2,026.0

2,545.9

Operating Income

2,534.4

2,209.8

3,664.6

8,994.8

4,994.0

4,407.1

Interest Expense, Total

-28.2

-30.2

-56.9

-57.3

-59.4

-72.1

Interest And Investment Income

—

—

75.4

45.8

160.1

417.7

Net Interest Expenses

-28.2

-30.2

18.5

-11.5

100.7

345.6

Other Non Operating Income (Expenses)

89.2

131.2

19.3

4.4

59.0

24.9

EBT, Excl. Unusual Items

2,595.4

2,310.8

3,702.4

8,987.7

5,153.7

4,777.6

Gain (Loss) On Sale Of Investments

-41.9

118.3

196.0

386.1

-39.8

-215.1

In Process R&D Expenses

—

—

-88.0

-48.0

-255.1

-186.1

Other Unusual Items

—

—

—

—

—

—

EBT, Incl. Unusual Items

2,553.5

2,429.1

3,810.4

9,325.8

4,858.8

4,376.4

Income Tax Expense

109.1

313.3

297.2

1,250.5

520.4

385.3

Earnings From Continuing Operations

2,444.4

2,115.8

3,513.2

8,075.3

4,338.4

3,991.1

Net Income

2,444.4

2,115.8

3,513.2

8,075.3

4,338.4

3,991.1

Net Income to Common Incl Extra Items

2,444.4

2,115.8

3,513.2

8,075.3

4,338.4

3,991.1

Net Income to Common Excl. Extra Items

2,444.4

2,115.8

3,513.2

8,075.3

4,338.4

3,991.1

Total Shares Outstanding

108.5

109.1

104.0

106.6

107.0

106.2

Weighted Avg. Shares Outstanding

107.9

109.2

107.6

105.7

107.1

106.8

Weighted Avg. Shares Outstanding Dil

114.8

114.6

115.1

112.2

113.5

113.8

EPS

22.7

19.4

32.7

76.4

40.5

37.4

EPS Diluted

21.3

18.5

30.5

72.0

38.2

35.1

EBITDA

2,682.6

2,420.1

3,900.5

9,281.0

5,335.4

4,815.2